Examinando por Autor "Aldanondo Aristizabal, Garazi"
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Ítem Development of a women’s empowerment nurse-led group intervention for benzodiazepine and Z-Hypnotic deprescription in primary healthcare: results of a co-creation process(John Wiley and Sons Inc, 2026-10-01) Cuesta Zigorraga, Amaia ; Las Hayas Rodríguez, Carlota ; Aldanondo Aristizabal, Garazi ; Sánchez Sánchez, ClaraAim: The aim of this study was to co-create a nurse-led women's empowerment group intervention to facilitate the deprescription of benzodiazepines and Z-hypnotics in primary care. Design: User-centred design based on co-creation. Methods: A literature review was conducted to identify female empowerment programmes that served as an initial prototype. The subsequent user-centred design applied a co-creation methodology in two structured phases: (1) Exploratory, to identify contextual needs and barriers, and (2) Development, to collaboratively define the intervention's final structure and content. Participants included chronic users of benzodiazepines and Z-hypnotics and primary care professionals (doctors, nurses, and pharmacists) who actively engaged in the collaborative design process. Results: The Exploratory phase identified structural and clinical deprescribing barriers, and female clients' knowledge gaps. Empowerment was confirmed as a key facilitator. The Development phase prioritised content (self-esteem, self-image, and healthcare) and adjusted the group intervention's format (duration, frequency, and structure) based on participant input. Conclusion: The co-creation process resulted in an eight-session intervention, with support cards and a training video for nurse-facilitators. This collaboration ensured the final design was precisely tailored to women's needs and clinical practice, maximising its feasibility and relevance. The intervention facilitates the tapering of benzodiazepines and Z-hypnotics by combining women's empowerment with individualised and supervised dose reduction by primary care clinicians. What Does This Paper Contribute to the Wider Global Clinical Community?: Demonstrates how co-creation with clients and healthcare professionals can lead to contextually adapted nurse-led interventions centred on women's empowerment. Highlights the role of women's empowerment as a catalyst for deprescribing long-term benzodiacepines and Z-hypnotics in primary healthcare. Introduces a structured and co-created eight-session intervention supported by a nurse-training video and support cards, offering practical toolkits. Public Contribution: Clients (as users) and primary care healthcare professionals actively participated in the design of the intervention aimed at empowering women. Their involvement included participation in co-creation workshops, in which needs and everyday realities relevant to the process of deprescribing benzodiazepines and Z-hypnotics were identified. The structure and content of the group intervention, as well as its relevance and feasibility, were defined collaboratively. This direct participation made it possible to develop an intervention that was more client-centred, equitable, and aligned with clinical practice. Reporting Method: This manuscript follows the short-form Guidance for Reporting Patient and Public Involvement (GRIPP2) checklist (Staniszewska et al., 2017) to ensure transparent reporting of the co-creation process, in which clients and healthcare professionals actively participated in the design, development, and evaluation of the intervention (Additional file 1. GRIPP 2).Ítem Pharmacokinetic evaluation of new drugs using a multi-labelling approach and PET imaging: application to a drug candidate with potential application in neuromuscular disorders(MDPI, 2023-01-18) Passannante, Rossana; Gómez Vallejo, Vanessa; Sagartzazu Aizpurua, Maialen; Vignau Arsuaga, Laura; Marco Moreno, Pablo; Aldanondo Aristizabal, Garazi ; Vallejo Illarramendi, Ainara; Aguiar Fernández, Pablo; Cossío, Unai; Martín, Abraham; Bergare, Jonas; Kingston, Lee; Elmore, Charles S.; Morcillo Alonso, Miguel Ángel ; Ferrón, Pablo; Aizpurua Iparraguirre, Jesus Mari ; Llop, JordiBackground and objective: The determination of pharmacokinetic properties of new chemical entities is a key step in the process of drug development. Positron emission tomography (PET) is an ideal technique to obtain both biodistribution and pharmacokinetic parameters of new compounds over a wide range of chemical modalities. Here, we use a multi-radionuclide/multi-position labelling approach to investigate distribution, elimination, and metabolism of a triazole-based FKBP12 ligand (AHK2) with potential application in neuromuscular disorders. Methods: Target engagement and stabilizing capacity of the drug candidate (AHK2) towards FKBP12-RyR was evaluated using competitive ligand binding and proximity ligation assays, respectively. Subsequently, AHK2 was labelled either with the positron emitter carbon-11 (11C) via 11C-methylation to yield both [11C]AHK2.1 and [11C]AHK2.2, or by palladium-catalysed reduction of the corresponding 5-iodotriazole derivative using 3H gas to yield [3H]AHK2. Metabolism was first investigated in vitro using liver microsomes. PET imaging studies in rats after intravenous (IV) administration at different doses (1 µg/Kg and 5 mg/Kg) were combined with determination of arterial blood time-activity curves (TACs) and analysis of plasma samples by high performance liquid chromatography (HPLC) to quantify radioactive metabolites. Arterial TACs were obtained in continuous mode by using an in-house developed system that enables extracorporeal blood circulation and continuous measurement of radioactivity in the blood. Pharmacokinetic parameters were determined by non-compartmental modelling of the TACs. Results: In vitro studies indicate that AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. [11C]AHK2.1, [11C]AHK2.2 and [3H]AHK2 could be obtained in overall non-decay corrected radiochemical yields of 14 ± 2%, 15 ± 2% and 0.05%, respectively. Molar activities were 60–110 GBq/µmol, 68–122 GBq/µmol and 0.4–0.5 GBq/μmol, respectively. In vitro results showed that oxidation of the thioether group into sulfoxide, demethylation of the CH3O-Ar residue and demethylation of –N(CH3)2 were the main metabolic pathways. Fast metabolism was observed in vivo. Pharmacokinetic parameters obtained from metabolite-corrected arterial blood TACs showed a short half-life (12.6 ± 3.3 min). Dynamic PET imaging showed elimination via urine when [11C]AHK2.2 was administered, probably reflecting the biodistribution of [11C]methanol as the major metabolite. Contrarily, accumulation in the gastrointestinal track was observed after administration of [11C]AKH2.1. Conclusions: AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. Studies performed with the 3H- and 11C-labelled FKBP12/RyR stabilizer AHK2 confirm fast blood clearance, linear pharmacokinetics and rapid metabolism involving oxidation of the sulfide and amine moieties and oxidative demethylation of the CH3-O-Ar and tertiary amine groups as the main pathways. PET studies suggest that knowledge about metabolic pathways is paramount to interpret images.